Compounds > lutetium
Page last updated: 2024-08-22

lutetium and docetaxel anhydrous

lutetium has been researched along with docetaxel anhydrous in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Hoffman, TJ; Johnson, CV; Ma, L; Perry, MC; Shelton, T; Smith, CJ; Volkert, WA1
Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE1
Bodei, L; Ezziddin, S; Jilg, CA; Lassmann, M; Luster, M; Maecke, HR; Ohlmann, CH; Olbert, PJ; Pfestroff, A1
Tagawa, ST1
Aragon-Ching, JB; Atiq, M; Chandran, E; Karzai, F; Madan, RA1
Das, CK; Goyal, S; Mavuduru, RS; Mittal, BR; Satapathy, S; Shukla, J; Singh, SK; Sood, A1

Reviews

1 review(s) available for lutetium and docetaxel anhydrous

ArticleYear
Emerging treatment options for prostate cancer.
    Expert review of anticancer therapy, 2023, Volume: 23, Issue:6

    Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant

2023

Trials

1 trial(s) available for lutetium and docetaxel anhydrous

ArticleYear
[
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023, Volume: 64, Issue:11

    Topics: Dipeptides; Docetaxel; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Outcome

2023

Other Studies

4 other study(ies) available for lutetium and docetaxel anhydrous

ArticleYear
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
    Cancer biotherapy & radiopharmaceuticals, 2006, Volume: 21, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Bombesin; Docetaxel; Estramustine; Female; Lutetium; Male; Mice; Mice, SCID; Models, Molecular; Peptide Fragments; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Bombesin; Taxoids; Tumor Protein, Translationally-Controlled 1; Xenograft Model Antitumor Assays

2006
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    The Prostate, 2009, Jan-01, Volume: 69, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays

2009
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
    European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:13

    Topics: Antigens, Surface; Clinical Trials as Topic; Docetaxel; Europe; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Oligopeptides; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids

2015
PSMA-targeted therapy in prostate cancer.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Antibodies, Bispecific; Antibodies, Neoplasm; Antigens, Surface; Biomarkers, Tumor; Clinical Trials as Topic; Dipeptides; Docetaxel; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lutetium; Male; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Randomized Controlled Trials as Topic

2021